These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of prostaglandins and blockers of prostaglandin synthesis on the ductus arteriosus: animal and human studies. Heymann MA; Rudolph AM Adv Prostaglandin Thromboxane Res; 1978; 4():363-72. PubMed ID: 645512 [No Abstract] [Full Text] [Related]
8. Prostaglandin treatment of newborns with ductal-dependent congenital heart disease. Linday LA; Engle MA Pediatr Ann; 1981 Apr; 10(4):29-38. PubMed ID: 7232040 [No Abstract] [Full Text] [Related]
9. The ductus arteriosus: why and how to manipulate its patency. Drummond WH; Bucciarelli RL; Gessner IH J Fla Med Assoc; 1983 Sep; 70(9):788-93. PubMed ID: 6355376 [No Abstract] [Full Text] [Related]
10. Clinical use of prostaglandins and prostaglandin synthetase inhibitors in cardiac problems of the newborn. Olley PM; Coceani F; Rowe RD; Swyer PR Adv Prostaglandin Thromboxane Res; 1980; 7():913-6. PubMed ID: 6768235 [No Abstract] [Full Text] [Related]
11. [Treatment of ductus-dependent congenital heart diseases with prostaglandin E1]. Lillquist K Ugeskr Laeger; 1979 Jul; 141(28):1915-6. PubMed ID: 473414 [No Abstract] [Full Text] [Related]
12. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects. Park IS; Nihill MR; Titus JL J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824 [No Abstract] [Full Text] [Related]
13. [Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects]. Kertész E; Hencz P; Tekulics P; Beviz J; Száva J; Matkó I; Kovács G Orv Hetil; 1980 May; 121(20):1197-9. PubMed ID: 7413203 [No Abstract] [Full Text] [Related]
14. Role of prostaglandin E1 and E2 in the management of neonatal heart disease. Olley PM; Coceani F; Rowe RD Adv Prostaglandin Thromboxane Res; 1978; 4():345-53. PubMed ID: 645511 [No Abstract] [Full Text] [Related]
15. [Long-term treatment using prostaglandin E2 in congenital heart defects with the pulmonary circulation being supplied by a patent ductus arteriosus]. Hruda J; Samánek M; First T; Vorísková M; Skovránek J Cesk Pediatr; 1985 May; 40(5):257-62. PubMed ID: 3860302 [No Abstract] [Full Text] [Related]
16. Use of prostaglandins in cardiopulmonary diseases of the newborn. Olley PM; Coceani F Semin Perinatol; 1980 Apr; 4(2):135-41. PubMed ID: 6990504 [No Abstract] [Full Text] [Related]
17. Letter: Medical manipulation of the ductus arteriosus. Christensen NC; Fabricus J Lancet; 1975 Aug; 2(7931):406-7. PubMed ID: 51207 [No Abstract] [Full Text] [Related]
18. Prostaglandin E1 infusion: successful initial treatment. Linday L; Levin AR; Reitman M; Engle MA N Y State J Med; 1981 Feb; 81(2):218-21. PubMed ID: 6936640 [No Abstract] [Full Text] [Related]
19. Histopathology of the ductus arteriosus after prostaglandin E1 administration in ductus dependent cardiac anomalies. Gittenberger-de Groot AC; Moulaert AJ; Harinck E; Becker AE Br Heart J; 1978 Mar; 40(3):215-20. PubMed ID: 637973 [TBL] [Abstract][Full Text] [Related]